Association of post-operative ctDNA detection with outcomes of patients with early breast cancers.

ABSTRACT:

Background

In early breast cancer (EBC) patients, we aimed to determine whether circulating tumor DNA (ctDNA) analysis following primary surgery, before systemic therapy, identified molecular residual disease and was associated with risk of relapse and relapse-free survival (RFS).

Methods

Plasma was collected, retrospectively, before surgery, 1-14 weeks post-operatively, and before adjuvant therapy, and in a subset of patients after adjuvant therapy. A personalized, tumor-informed, multiplex PCR next generation sequencing assay (Signatera™) was used for ctDNA detection and quantification. The primary objective was to compare RFS and distant recurrence-free survival (DRFS) in patients with detected versus non-detected ctDNA.

Results

A total of 48 patients with EBC (med

SUBMITTER: Cutts R 

PROVIDER: S-EPMC11402396 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature